Wednesday, 13 Dec 2017

You are here

Lupus Hospitalizations are Common

Patients with systemic lupus erythematosus (SLE) incur substantial morbidity and complications that may lead to hospitalizations and increased cost of lupus care. Researchers from the University Health Network in Toronto have published a review of SLE hospitalizations showing thta while commone (for either infection or lupus activity), only 2.8% of hospitalizations resulted in death.

They identified all SLE hospitalizations at University Health Network between 2011–2012 and 2013–2015 to assess cause, extent of hospitalizations, and outcomes. 

They identified 247 SLE patients with a total of 491 hospitalizations. Most (87.4%) were women, with an average age of 43.9 years, and a mean disease duration of 13.7 years.  Thus SLE patients was averaged 1.6 hospitalizations lasting 8.5 days.

Incidental causes, such as adverse drug reactions or pain, were the most common reason for admission (36.0%). Next most common were admissions were because of active SLE and infection (21.4% and 22.4%, respectively). ICU admission was required in 13% and 2.8% of hospitalizations resulted in death.

Fewer hospitalizations were seen in those who were employed, those on antimalarials or with higher educational level.

Damage related to lupus correlated with increased hospitalizations. and antimalarial use correlated with shorter length of stay. 

Re-hospitalization was seen in nearly 40% of patients. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease.

EULAR/ACR SLE Classification Criteria Update

Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.